ANTIISHEMIJSKA TERAPIJA U LEČENJU HRONIČNOG KORONARNOG SINDROMA
Sažetak
Ishemija srčanog mišića ima, kao patofiziološku osnovu, neadekvatan odnos između snabdevenosti i potreba miokarda za oksigenisanom krvlju. Klinički se manifestuje kao anginozni bol sa tipičnom lokalizacijom, karakterom, intenzitetom i pratećim tegobama, pre svega netolerancijom napora. Dijagnostički algoritam obuhvata klinički pregled, neinvanzivne i invazivne dijagnostičke procedure, uključujući koronarografiju kao zlatni standard. Konzervativno lečenje stabilne angine pektoris, sem modifikacije načina života i eliminisanja tradicionalnih faktora rizika, podrazumeva primenu savremenih lekova, među kojima je i ranolazin, koji se izdvojio svojim jedinstvenim mehanizmom dejstva, efikasnošću i bezbednošću. Ranolazin je efikasan u redukciji manifestacija ishemije i angine sa potencijalnim efektom na disfunkciju leve komore – pre svega dijastolnu i električnu nestabilnost.
Reference
Morrow DA, Boden WE. Chapter 57: Stable Ischemic Heart Disease. In: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 9th ed. (2012). Saunders; 1210-1269.
Mozaffarian D, Bryson CL, Spertus JA, McDonell MB, Fihn SD. Anginal symptoms consistently predict total mortality among outpatients with coronary artery disease. Am Heart J. 2003 Dec;146(6):1015-22. doi: 10.1016/S0002-8703(03)00436-8.
Michel T, Hoffman BB. Chapter 27: Treatment of myocardial Ischemia & Hypertension. In: Brunton LL, et al. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 12th ed. (2011).
Summary of drug characteristics for Ranexa, February 2021.
Stone PH. Ranolazine: new paradigm for management of myocardial ischemia, myocardial dysfunction, and arrhythmias. Cardiol Clin. 2008 Nov;26(4):603-14. doi: 10.1016/j.ccl.2008.06.002.
Ferrari R, Camici PG, Crea F, Danchin N, Fox K, Maggioni AP, et al. Expert consensus document: A 'diamond' approach to personalized treatment of angina. Nat Rev Cardiol. 2018 Feb;15(2):120-132. doi: 10.1038/nrcardio.2017.131.
Chaitman BR. Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Circulation. 2006 May 23;113(20):2462-72. doi: 10.1161/CIRCULATIONAHA.105.597500.
Hasenfuss G, Maier LS. Mechanism of action of the new anti-ischemia drug ranolazine. Clin Res Cardiol. 2008 Apr;97(4):222-6. doi: 10.1007/s00392-007-0612-y.
Stone PH, Chaitman BR, Stocke K, Sano J, DeVault A, Koch GG. The anti-ischemic mechanism of action of ranolazine in stable ischemic heart disease. J Am Coll Cardiol. 2010 Sep 14;56(12):934-42. doi: 10.1016/j.jacc.2010.04.042.
Keating GM. Ranolazine: a review of its use in chronic stable angina pectoris. Drugs. 2008;68(17):2483-503. doi: 10.2165/0003495-200868170-00006.
Wenger NK, Chaitman B, Vetrovec GW. Gender comparison of efficacy and safety of ranolazine for chronic angina pectoris in four randomized clinical trials. Am J Cardiol. 2007 Jan 1;99(1):11-8. doi: 10.1016/j.amjcard.2006.07.052.
Timmis AD, Chaitman BR, Crager M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J. 2006 Jan;27(1):42-8. doi: 10.1093/eurheartj/ehi495.
Jurisch D, Laufs U. Chronisches Koronarsyndrom : Neuklassifikation der stabilen koronaren Herzkrankheit [Chronic coronary syndrome : New classification of stable coronary artery disease]. Internist (Berl). 2021 Jan;62(1):47-57. German. doi: 10.1007/s00108-020-00910-0.
Manolis AJ, Kallistratos MS, Poulimenos LΕ, Ambrosio G, Dechend R, Lopez-Sendon J, et al. The ESC 2019 CCS guidelines: Have we left our patients and scientific evidence behind? Eur J Intern Med. 2020 Feb;72:5-8. doi: 10.1016/j.ejim.2019.12.012.
Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, et al; ESC Scientific Document Group. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024 Sep 29;45(36):3415-3537. doi: 10.1093/eurheartj/ehae177.
Rousseau MF, Pouleur H, Cocco G, Wolff AA. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol. 2005 Feb 1;95(3):311-6. doi: 10.1016/j.amjcard.2004.09.025.
Chaitman BR, Skettino SL, Parker JO, Hanley P, Meluzin J, Kuch J, et al; MARISA Investigators. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004 Apr 21;43(8):1375-82. doi: 10.1016/j.jacc.2003.11.045.
Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J, et al; Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004 Jan 21;291(3):309-16. doi: 10.1001/jama.291.3.309.
Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L; ERICA Investigators. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol. 2006 Aug 1;48(3):566-75. doi: 10.1016/j.jacc.2006.05.044.
Kosiborod M, Arnold SV, Spertus JA, McGuire DK, Li Y, Yue P, et al. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). J Am Coll Cardiol. 2013 May 21;61(20):2038-45. doi: 10.1016/j.jacc.2013.02.011.
Koren MJ, Crager MR, Sweeney M. Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE). J Am Coll Cardiol. 2007 Mar 13;49(10):1027-34. doi: 10.1016/j.jacc.2006.10.067.
Wilson SR, Scirica BM, Braunwald E, Murphy SA, Karwatowska-Prokopczuk E, Buros JL, et al. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial. J Am Coll Cardiol. 2009 Apr 28;53(17):1510-6. doi: 10.1016/j.jacc.2009.01.037.
Venkataraman R, Belardinelli L, Blackburn B, Heo J, Iskandrian AE. A study of the effects of ranolazine using automated quantitative analysis of serial myocardial perfusion images. JACC Cardiovasc Imaging. 2009 Nov;2(11):1301-9. doi: 10.1016/j.jcmg.2009.09.006.
Ayyasamy L, Bagepally BS. Cost-utility of Ranolazine for Chronic Stable Angina Pectoris: Systematic Review and Meta-analysis. Clin Ther. 2023 May;45(5):458-465. doi: 10.1016/j.clinthera.2023.04.004.
Maier LS, Layug B, Karwatowska-Prokopczuk E, Belardinelli L, Lee S, Sander J, et al. RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study. JACC Heart Fail. 2013 Apr;1(2):115-22. doi: 10.1016/j.jchf.2012.12.002.
Cempaka Putri DKS, Andrianto A, Al-Farabi MJ, Saputra PBT, Nugraha RA. Efficacy of Ranolazine to Improve Diastolic Performance in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-analysis. Eur Cardiol. 2023 Jan 21;18:e02. doi: 10.15420/ecr.2022.10.
Zareba W, Daubert JP, Beck CA, Huang DT, Alexis JD, Brown MW, et al; RAID Trial Investigators. Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators: The RAID Trial. J Am Coll Cardiol. 2018 Aug 7;72(6):636-645. doi: 10.1016/j.jacc.2018.04.086.
Leelapatana P, Thongprayoon C, Prasitlumkum N, Vallabhajosyula S, Cheungpasitporn W, Chokesuwattanaskul R. Role of Ranolazine in the Prevention and Treatment of Atrial Fibrillation in Patients with Left Ventricular Systolic Dysfunction: A Meta-Analysis of Randomized Clinical Trials. Diseases. 2021 Apr 16;9(2):31. doi: 10.3390/diseases9020031.
Miles RH, Passman R, Murdock DK. Comparison of effectiveness and safety of ranolazine versus amiodarone for preventing atrial fibrillation after coronary artery bypass grafting. Am J Cardiol. 2011 Sep 1;108(5):673-6. doi: 10.1016/j.amjcard.2011.04.017.
